Biogen stock up following good news for compeititor, Genzyme

On Friday, some good news for a Genzyme Corp., competitor of Biogen Idec (Nasdaq: BIIB) in the multiple sclerosis market, also became good news for Biogen, boosting it’s stock price more than 5 percent by mid-day...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.